Strategic Acquisition Cook Pharmica was acquired by Catalent Pharma Solutions in 2017 for a substantial $950 million, signifying a strong position within the biologics contract development and manufacturing sector, which suggests potential opportunities for collaboration or service expansion within similar biopharma segments.

Biologics Focus As a biologics-focused contract organization, Cook Pharmica specializes in development and manufacturing services for biologics, making it a key partner for companies seeking expertise in advanced biologic therapies and related innovative treatments.

Market Scale With a revenue estimated between $50 million and $100 million and around 51-200 employees, Cook Pharmica operates within a growing biotech niche, offering opportunities for targeted sales efforts toward mid-sized biotech firms seeking reliable manufacturing partners.

Technology Stack Utilizing industry-standard digital tools like Google Analytics, Facebook Pixel, and LiveChat, Cook Pharmica maintains active digital engagement, indicating openness to technology-driven solutions and digital marketing partnerships.

Competitive Landscape Positioned alongside industry giants such as Samsung Biologics and WuXi AppTec, Cook Pharmica offers an accessible entry point for innovative biotech companies seeking high-quality, flexible biologics manufacturing services within a competitive yet specialized market.